Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides ...

New York, USA, July 10, 2025 (GLOBE NEWSWIRE) -- Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight ...

BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, ...

The observation that many cancers in adults arise in the setting of chronic inflammation has opened up a research field that has been crucial for our understanding and ultimately has established a new ...

Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma Without MYCN Amplification: Results of the Prospective INES 99.1 Median age at registration was ...

Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma. If you have the appropriate software installed, you can download article citation data to the citation ...

Interleukin-2 (IL-2) is a vital cytokine in adoptive cell therapy that plays an important part in the stimulation and growth of immune cells as well as Tumor-Infiltrating Lymphocytes (TIL), Chimeric ...

A study in the journal Science Immunology now shows how two subsets of one type of immune cell — the CD8 T cell — develop to provide either short-term or long-term immune protection. The study focuses ...